Chang Liu

This paper develops a non-viral BCMA CAR-T therapy using CRISPR and 1XX signaling, showing improved safety, potency, and persistence in multiple myeloma.

This paper develops a genome engineering workflow for primary human NK cells using CRISPR/Cas9 and AAV6 to integrate and disrupt genes, enhancing anti-tumor function through targeted CAR expression.

The paper shows that indels, not just missense mutations, enable antiviral proteins like TRIM5 to evolve new functions against viruses.

This paper develops a method to efficiently reprogram T cells at multiple loci using SEED-Selection, achieving high purity for single and combined gene edits.